Jan Joseph Melenhorst

List of Publications by Year
in descending order

213	24,416	24978 57	7718 150
papers	citations	h-index	g-index

221	221	221	20051
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New England Journal of Medicine, 2014, 371, 1507-1517.	13.9	4,444
2	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7, 303ra139.	5.8	1,402
3	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. New England Journal of Medicine, 2017, 377, 2545-2554.	13.9	1,390
4	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine, 2018, 24, 563-571.	15.2	1,150
5	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, 2017, 9, .	5.8	1,116
6	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery, 2015, 5, 1282-1295.	7.7	997
7	CRISPR-engineered T cells in patients with refractory cancer. Science, 2020, 367, .	6.0	872
8	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery, 2016, 6, 664-679.	7.7	811
9	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, 558, 307-312.	13.7	574
10	B cell maturation antigenâ€“specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 2019, 129, 2210-2221.	3.9	513
11	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1040-1047.	13.9	511
12	Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. Journal of Clinical Investigation, 2016, 126, 3814-3826.	3.9	472
13	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, 2018, 24, 1499-1503.	15.2	459
14	Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight, 2018, 3, .	2.3	412
15	Dominant-Negative TGF-Î² Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular Therapy, 2018, 26, 1855-1866.	3.7	406
16	PD-1 blockade modulates chimeric antigen receptor (CAR)â€“modified T cells: refueling the CAR. Blood, 2017, 129, 1039-1041.	0.6	393
17	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, 127, 1117-1127.	0.6	381
18	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature, 2022, 602, 503-509.	13.7	369

#	Article	IF	Citations
19	Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Critical Care Medicine, 2017, 45, e124-e131.	0.4	357
20	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology, 2018, 155, 29-32.	0.6	337
21	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunology Research, 2017, 5, 1152-1161.	1.6	309
22	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood, 2017, 130, 2317-2325.	0.6	273
23	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Molecular Therapy, 2019, 27, 1919-1929.	3.7	220
24	Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood, 2003, 102, 2892-2900.	0.6	204
25	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood, 2016, 128, 360-370.	0.6	190
26	Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunology Research, 2018, 6, 1100-1109.	1.6	189
27	Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood, 2010, 116, 4700-4702.	0.6	176
28	PSMA-targeting TGFÎ²-insensitive armored CAR Tâ€‰cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine, 2022, 28, 724-734.	15.2	171
29	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. Journal of Immunological Methods, 2016, 434, 1-8.	0.6	150
30	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, 2018, 3, .	2.3	140
31	Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. Journal of Immunological Methods, 2009, 340, 11-24.	0.6	134
32	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances, 2019, 3, 2812-2815.	2.5	133
33	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood, 2019, 134, 44-58.	0.6	118
34	Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019). Blood, 2015, 126, 681-681.	0.6	116
35	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Molecular Therapy, 2014, 22, 1388-1395.	3.7	106
36	Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia, 2017, 31, 246-248.	3.3	106

#	Article	IF	Citations
37	Differential Association of Programmed Death-1 and CD57 with Ex Vivo Survival of CD8+ T Cells in HIV Infection. Journal of Immunology, 2009, 183, 1120-1132.	0.4	105
38	Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia, 2013, 27, 1538-1547.	3.3	104
39	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 2862-2871.	0.8	102
40	Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood, 2003, 101, 1752-1758.	0.6	101
41	Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood, 2017, 130, 2569-2572.	0.6	98
42	Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.. Journal of Clinical Oncology, 2016, 34, 3011-3011.	0.8	98
43	In vitro Induction of Myeloid Leukemiaâ€“Specific CD4 and CD8 T Cells by CD40 Ligand â€“ Activated B Cells Gene Modified to Express Primary Granule Proteins. Clinical Cancer Research, 2005, 11, 4495-4503.	3.2	96
44	CMV-specific T cells generated from naÃ¯ve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine, 2015, 7, 285ra63.	5.8	93
45	Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood, 2004, 103, 4588-4593.	0.6	92
46	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy, 2018, 26, 269-279.	3.7	90
47	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1468956.	2.1	88
48	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy, 2020, 5, 134.	7.1	84
49	Bone Marrow Mesenchymal Stromal Cells to Treat Tissue Damage in Allogeneic Stem Cell Transplant Recipients: Correlation of Biological Markers with Clinical Responses. Stem Cells, 2014, 32, 1278-1288.	1.4	83
50	The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood, 2009, 114, 5071-5080.	0.6	82
51	Neurotoxicity after CTL019 in a pediatric and young adult cohort. Annals of Neurology, 2018, 84, 537-546.	2.8	82
52	The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2017, 35, 103-103.	0.8	80
53	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. Journal of Clinical Investigation, 2019, 130, 673-685.	3.9	78
54	T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood, 2011, 117, 2691-2699.	0.6	77

#	Article	IF	Citations
55	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. Blood, 2018, 132, 298-298.	0.6	73
56	Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas. Blood, 2018, 132, 4198-4198.	0.6	71
57	Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. Blood, 2015, 126, 183-183.	0.6	65
58	Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Science Advances, 2022, 8, .	4.7	63
59	Engineering-enhanced CAR T cells for improved cancer therapy. Nature Cancer, 2021, 2, 780-793.	5.7	60
60	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology, 2018, 9, 2740.	2.2	58
61	Nonviral RNA chimeric antigen receptorâ€“modified T cells in patients with Hodgkin lymphoma. Blood, 2018, 132, 1022-1026.	0.6	58
62	High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood, 2009, 113, 2238-2244.	0.6	57
63	B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. Blood, 2016, 128, 1147-1147.	0.6	56
64	Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood, 2016, 128, 217-217.	0.6	52
65	Techniques to improve the direct ex vivo detection of low frequency antigenâ€specific CD8⁺ T cells with peptideâ€major histocompatibility complex class I tetramers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1001-1009.	1.1	49
66	Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Research, 2015, 14, 95-104.	0.3	48
67	KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. Blood, 2012, 119, 1511-1521.	0.6	45
68	iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. Genome Biology, 2019, 20, 14.	3.8	45
69	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. Journal of Clinical Investigation, 2021, 131, .	3.9	45
70	Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Advances, 2022, 6, 5774-5785.	2.5	43
71	Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. British Journal of Haematology, 2002, 119, 97-105.	1.2	42
72	Large granular lymphocyte leukaemia is characterized by a clonal T-cell receptor rearrangement in both memory and effector CD8+ lymphocyte populations. British Journal of Haematology, 2001, 112, 189-194.	1.2	40

#	Article	IF	Citations
73	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. Blood, 2015, 126, 3769-3769.	0.6	40
74	Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL. Blood, 2014, 124, 1982-1982.	0.6	38
75	Allogeneic HLA-A*02â€“Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target Promiscuity. Journal of Immunology, 2011, 187, 2824-2833.	0.4	37
76	Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells. Blood, 2014, 124, 2296-2296.	0.6	37
77	Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation. Haematologica, 2012, 97, 867-873.	1.7	34
78	Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Frontiers in Oncology, 2021, 11, 669071.	1.3	34
79	Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 3007-3007.	0.8	33
80	Detection of low avidity CD8+ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. Journal of Immunological Methods, 2008, 338, 31-39.	0.6	32
81	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular Therapy, 2020, 28, 2367-2378.	3.7	32
82	Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2016, 34, 7002-7002.	0.8	32
83	Mechanisms of resistance to CAR T cell therapies. Seminars in Cancer Biology, 2020, 65, 91-98.	4.3	31
84	Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. , 2021, 9, e002328.		31
85	T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. The Hematology Journal, 2003, 4, 18-25.	2.0	31
86	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. Blood, 2016, 128, 5702-5702.	0.6	31
87	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. Blood, 2016, 128, 652-652.	0.6	31
88	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Advances, 2020, 4, 5174-5183.	2.5	30
89	CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.. Journal of Clinical Oncology, 2017, 35, 7509-7509.	0.8	30
90	Both Naiˆve and Memory T-Cell Subsets Participate in Alloresponses to HLA-Mismatched Targets â€“ Implications for Adoptive Transfer of Viral Antigen-Specific T Cells.. Blood, 2009, 114, 2439-2439.	0.6	30

#	Article	IF	Citations
91	Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5511-5511.	0.8	29
92	Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome. Biology of Blood and Marrow Transplantation, 2011, 17, 1846-1854.	2.0	28
93	Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells. Molecular Therapy, 2015, 23, 179-183.	3.7	28
94	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. Blood, 2016, 128, 974-974.	0.6	28
95	A phase I clinical trial of PSMA-directed/TGFÎ²-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, TPS347-TPS347.	0.8	28
96	A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptorâ€“positive cells. Blood, 2020, 135, 505-509.	0.6	25
97	Alloreactivity Across HLA Barriers Is Mediated by Both NaÃ¯ve and Antigen-Experienced T Cells. Biology of Blood and Marrow Transplantation, 2011, 17, 800-809.	2.0	24
98	Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood, 2012, 119, 368-376.	0.6	24
99	Robust Expansion of Viral Antigen-specific CD4+ and CD8+ T Cells for Adoptive T Cell Therapy Using Gene-modified Activated T Cells as Antigen Presenting Cells. Journal of Immunotherapy, 2006, 29, 436-443.	1.2	23
100	Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant. Haematologica, 2013, 98, 346-352.	1.7	22
101	Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19. Blood, 2013, 122, 163-163.	0.6	22
102	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. Blood, 2015, 126, 683-683.	0.6	22
103	Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.. Journal of Clinical Oncology, 2016, 34, 3009-3009.	0.8	22
104	The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements. Journal of Immunological Methods, 2007, 321, 107-120.	0.6	21
105	Toward precision manufacturing of immunogene T-cell therapies. Cytotherapy, 2018, 20, 623-638.	0.3	21
106	Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis*. Critical Care Medicine, 2020, 48, 344-352.	0.4	20
107	Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies. Clinical Cancer Research, 2004, 10, 1047-1056.	3.2	19
108	Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. Blood, 2020, 136, 1980-1983.	0.6	19

#	Article	IF	Citations
109	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. Blood, 2018, 132, 1886-1886.	0.6	19
110	Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. Blood, 2011, 117, 5250-5256.	0.6	18
111	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 57-57.	0.6	18
112	Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. Blood, 2003, 102, 3786-3792.	0.6	17
113	Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. Journal of the American Academy of Dermatology, 2016, 75, 1054-1057.	0.6	17
114	Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas. Blood, 2016, 128, 3026-3026.	0.6	17
115	Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2067-2067.	0.8	17
116	Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.. Journal of Clinical Oncology, 2016, 34, 3007-3007.	0.8	17
117	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cellâ€“Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clinical Cancer Research, 2022, 28, 3804-3813.	3.2	17
118	Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR. Blood, 2016, 128, 281-281.	0.6	16
119	Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2017, 35, 10507-10507.	0.8	16
120	The proliferation associated nuclear element (PANE1) is conserved between mammals and fish and preferentially expressed in activated lymphoid cells. Gene Expression Patterns, 2004, 4, 389-395.	0.3	15
121	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6580-6590.	3.2	15
122	Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors. Blood, 2019, 134, 622-622.	0.6	15
123	Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy. Blood, 2016, 128, 1100-1100.	0.6	15
124	Contribution ofTCR-Î² Locus and HLA to the Shape of the Mature Human VÎ² Repertoire. Journal of Immunology, 2008, 180, 6484-6489.	0.4	14
125	Biomarkers in chimeric antigen receptor T-cell therapy. Biomarkers in Medicine, 2018, 12, 415-418.	0.6	14
126	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. Blood, 2014, 124, 380-380.	0.6	14

#	Article	IF	Citations
127	Endothelial Biomarkers Are Associated With Indirect Lung Injury in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome. , 2020, 2, e0295.		14
128	Timing and intensity of exposure to interferonâ€Î³ critically determines the function of monocyteâ€derived dendritic cells. Immunology, 2014, 143, 96-108.	2.0	13
129	CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy. Methods in Molecular Biology, 2020, 2121, 213-239.	0.4	13
130	PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells. Blood, 2018, 132, 1973-1973.	0.6	13
131	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. Blood, 2019, 134, 1863-1863.	0.6	13
132	Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. Blood, 2014, 124, 3087-3087.	0.6	13
133	IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v110.4-v111.	0.6	10
134	Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM). Blood, 2018, 132, 1974-1974.	0.6	10
135	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Blood, 2019, 134, 49-49.	0.6	10
136	STAT3 Role in T-Cell Memory Formation. International Journal of Molecular Sciences, 2022, 23, 2878.	1.8	10
137	PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response. Frontiers in Immunology, 2022, 13, .	2.2	10
138	Aplastic anaemia in donor cells 14 years after bone-marrow transplant. Lancet, The, 1999, 353, 2037-2038.	6.3	9
139	Tumor vaccines and beyond. Cytotherapy, 2011, 13, 8-18.	0.3	9
140	Innovation and opportunity for chimeric antigen receptor targeted TÂcells. Cytotherapy, 2013, 15, 1046-1053.	0.3	9
141	Peripheral Blood T-Cell Fitness Is Diminished in Patients With Pancreatic Carcinoma but Can Be Improved With Homeostatic Cytokines. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 656-658.e6.	2.3	8
142	Engineered T Cell Therapies from a Drug Development Viewpoint. Engineering, 2019, 5, 140-149.	3.2	8
143	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Clinical and Experimental Medicine, 2020, 20, 469-480.	1.9	8
144	Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms. Blood, 2016, 128, 2159-2159.	0.6	8

#	Article	IF	Citations
145	Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).. Journal of Clinical Oncology, 2016, 34, 7564-7564.	0.8	8
146	Cancer stem cells: advances in biology and clinical translationâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2021, 1506, 142-163.	1.8	8
147	Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL). Cytotherapy, 2017, 19, S118-S119.	0.3	7
148	Next-generation CAR T cells to overcome current drawbacks. International Journal of Hematology, 2020, 114, 532-543.	0.7	7
149	Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. Blood, 2015, 126, 2523-2523.	0.6	7
150	Is Human Cell Therapy Research Caught in a Mousetrap?. Molecular Therapy, 2011, 19, 224-227.	3.7	6
151	CAR-T and ibrutinib vs CLL: sequential or simultaneous?. Blood, 2020, 135, 1611-1612.	0.6	6
152	Bâ€cell maturation antigen chimeric antigen receptor Tâ€cell reâ€expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitorâ€based combination therapy. British Journal of Haematology, 2021, 193, 851-855.	1.2	6
153	Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. Blood, 2014, 124, 1983-1983.	0.6	6
154	Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. Blood, 2013, 122, 3885-3885.	0.6	5
155	Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1334-1334.	0.6	5
156	Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer.. Journal of Clinical Oncology, 2017, 35, 3011-3011.	0.8	5
157	Allogeneic HLA-A2-Restricted WT1-Specific T Cells From Mismatched Donors Are Highly Reactive but Show Potentially Hazardous Promiscuity.. Blood, 2009, 114, 4081-4081.	0.6	5
158	Minor histocompatibility antigen discovery: turning up the HEATR. Blood, 2010, 115, 4630-4631.	0.6	4
159	Genetically engineered fixed K562 cells: potent â€œoff-the-shelfâ€•antigen-presenting cells for generating virus-specific T cells. Cytotherapy, 2014, 16, 135-146.	0.3	4
160	Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones. Blood, 2018, 132, 699-699.	0.6	4
161	Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma. Blood, 2019, 134, 1909-1909.	0.6	4
162	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. Blood, 2020, 136, 30-32.	0.6	4

#	Article	IF	Citations
163	Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies. Blood, 2014, 124, 966-966.	0.6	4
164	Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia. Blood, 2016, 128, 220-220.	0.6	4
165	Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 2812-2812.	0.6	4
166	A phase I clinical trial of PSMA-directed/TGFÎ²-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS269-TPS269.	0.8	4
167	Peptide-Major Histocompatibility Complex Class I Tetramers with Enhanced Coreceptor Binding Properties Enable Visualization of Low Avidity Leukemia-Associated Antigen-Specific CD8+ T Cells.. Blood, 2007, 110, 1343-1343.	0.6	4
168	Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy. Blood, 2014, 124, 1110-1110.	0.6	4
169	Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models. Blood, 2017, 130, 807-807.	0.6	4
170	B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?. Science Translational Medicine, 2022, 14, .	5.8	4
171	CT103A, a forward step in multiple myeloma immunotherapies. Blood Science, 2021, 3, 59-61.	0.4	3
172	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 807-816.	0.6	3
173	Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. , 2016, , .		3
174	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	1.5	3
175	LGL: a disease rediscovered. Blood, 2012, 120, 2932-2933.	0.6	2
176	Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells. , 2015, 3, .		2
177	Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vî²+ expansions. Scientific Reports, 2018, 8, 2534.	1.6	2
178	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy. Blood, 2018, 132, 235-235.	0.6	2
179	Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?. Blood, 2012, 120, 3283-3283.	0.6	2
180	Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control. Blood, 2016, 128, 4549-4549.	0.6	2

#	Article	IF	Citations
181	A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 681-681.	0.6	2
182	Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells. Blood, 2021, 138, 166-166.	0.6	2
183	Optimizing T-cell expansion: have we reached the limit?. Cytotherapy, 2009, 11, 813-814.	0.3	1
184	High Levels Of IL-27 Occur In Newly Diagnosed Acute Myeloid Leukemia (AML) and May Influence Outcome By Suppressing T Cell Function. Blood, 2013, 122, 2567-2567.	0.6	1
185	Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL.. Journal of Clinical Oncology, 2017, 35, 137-137.	0.8	1
186	Cell intrinsic PD-1 checkpoint blockade releases the brake on human chimeric antigen receptor (CAR) T cells for solid tumors. Translational Cancer Research, 2016, 5, S1328-S1332.	0.4	1
187	Widening the Applicability of Human Neutrophil Elastase and Proteinase 3 Peptide Vaccines by Elucidating Immunogenic Non-HLA-A2 MHC Class I Restricted Epitopes.. Blood, 2006, 108, 3708-3708.	0.6	1
188	Long-Term T Cell Immune Reconstitution in Patients Surviving 10 or More Years after Allogeneic Stem Cell Transplantation for Hematologic Malignancies. Blood, 2008, 112, 1173-1173.	0.6	1
189	Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size. Blood, 2013, 122, 3705-3705.	0.6	1
190	Abstract LB-053: Next-generation sequencing of T-cell receptor-beta gene rearrangements reveals dramatic expansion of T-cell clonotypes after CART-EGFRvIII therapy for glioblastoma. Cancer Research, 2017, 77, LB-053-LB-053.	0.4	1
191	Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19. Blood, 2021, 138, 167-167.	0.6	1
192	B-CLL Mediated Resistance to CAR T Cell Therapy Via Insufficient Activation Is CAR-Independent. Blood, 2020, 136, 44-44.	0.6	1
193	Do CARs finally hit the CLL road?. Blood, 2022, 139, 1775-1776.	0.6	1
194	Regulatory T cells from another bench: ready for the bedside?. Cytotherapy, 2013, 15, 1183-1184.	0.3	0
195	When one is better than two. Cytotherapy, 2013, 15, 139.	0.3	0
196	Ultra-Low Dose IL-2 Expands Natural Regulatory T Cells and CD56bright NK Cells in Patients and Healthy Donors and Is Associated with Clinical Improvement in Chronic Graft Versus Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, S147-S148.	2.0	0
197	High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies. Current Hematologic Malignancy Reports, 2021, 16, 112-116.	1.2	0
198	Improving and Maintaining Responses in Pediatric Bâ€“Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptorâ€“T Cell Therapy. Cancer Journal (Sudbury, Mass), 2021, 27, 151-158.	1.0	0

#	Article	IF	Citations
199	Abstract 1507: Chimeric antigen receptor T cells carrying IDH1 neomorph increase CD8 positive central memory proportion without interfering with cell growth. , 2021, , .		0
200	Human Neutrophil Elastase Stimulating CD4+ and CD8+ T Cells Is a Potential Protein Vaccine for Leukemia Patients with Diverse HLA Types.. Blood, 2007, 110, 1807-1807.	0.6	0
201	Identification of a Shared CD4+ and CD8+ T Cell Epitope within Human Neutrophil Elastase for Peptide Vaccination in HLA-A02 Negative Leukemia Patients.. Blood, 2007, 110, 1803-1803.	0.6	0
202	Evolution of the Donor T Cell Repertoire In Allogeneic Stem Cell Transplant Recipients In the Second Decade After Transplantation. Blood, 2010, 116, 831-831.	0.6	0
203	Engineering of Human T-Cells with a Novel Aurora-A Kinase-Specific T-Cell Receptor Gene Transfer Confers Anti-Leukemia Reactivity. Blood, 2010, 116, 4290-4290.	0.6	0
204	Low Thymic Natural Regulatory T Cell Output in the Donor Is Associated with An Increased Incidence of Extensive Chronic GvHD After T Cell Depleted Matched Sibling Stem Cell Transplantation (SCT). Blood, 2011, 118, 328-328.	0.6	0
205	KIT with D816 Mutations Cooperates with CBFB-MYH11 for Leukemogenesis in Mice. Blood, 2011, 118, 867-867.	0.6	0
206	Abstract 5377: Low donor thymic output predicts increased incidence of extensive chronic GVHD and worse overall survival after TCD-matched sibling SCT. , 2012, , .		0
207	Long Term Maintenance of Myeloid Leukemia Stem Cell-Like Populations Cultured with Mesenchymal Stromal Cells (MSC). Blood, 2012, 120, 3546-3546.	0.6	0
208	Improved Strategy for Rapid Generation of Quadrivirus-Specific CD8+ and CD4+ Cytotoxic T Lymphocytes (CTLs) for Adoptive Transfer After Stem Cell Transplantation (SCT). Blood, 2012, 120, 4121-4121.	0.6	0
209	Abrogation of Myeloid Derived Suppressor Cell-Like Inhibitory Activity of K562 Restores Antigen Presenting Cell Functions. Blood, 2012, 120, 4118-4118.	0.6	0
210	Phase 1 Trial Of Bone Marrow Stromal Cells (Bone Marrow-derived MSCS) To Treat Tissue Damage In Allogeneic Stem Cell Transplant Recipients: Biological Markers Correlate With Clinical Responses and Survival. Blood, 2013, 122, 3282-3282.	0.6	0
211	Graft Versus Leukemia Response without Graft Versus Host Disease Elicited By Adoptively Transferred Multivirus-Specific T-Cells. Blood, 2014, 124, 2439-2439.	0.6	0
212	Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer. Current Drug Targets, 2017, 18, 332-340.	1.0	0
213	Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4548-4548.	0.6	0